NCT05970237 A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
| NCT ID | NCT05970237 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Condition | Diabetes Mellitus |
| Study Type | OBSERVATIONAL |
| Enrollment | 9,000 participants |
| Start Date | 2023-07-26 |
| Primary Completion | 2025-10-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 9,000 participants in total. It began in 2023-07-26 with a primary completion date of 2025-10-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension
Eligibility Criteria
Inclusion Criteria: * Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab. * Those who voluntarily signed a written personal information agreement to participate in this clinical study. * Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion. Exclusion Criteria: * Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.) * Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1) * Those who are expected to need insulin prescription during the study period * Pregnant women, breast-feeding women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05970237 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05970237 currently recruiting?
Yes, NCT05970237 is actively recruiting participants. Contact the research team at syoh@boryung.co.kr for enrollment information.
Where is the NCT05970237 trial being conducted?
This trial is being conducted at Incheon, South Korea.
Who is sponsoring the NCT05970237 clinical trial?
NCT05970237 is sponsored by Boryung Pharmaceutical Co., Ltd. The trial plans to enroll 9,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.